Ovid Therapeutics Inc. (OVID) Covered Calls
You can sell covered calls on Ovid Therapeutics Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OVID (prices last updated Fri 4:16 PM ET):
| Ovid Therapeutics Inc. (OVID) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 1.06 | -0.09 | 0.99 | 1.11 | 437K | - | 0.1 |
| Covered Calls For Ovid Therapeutics Inc. (OVID) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 2.5 | 0.00 | 1.11 | 0.0% | 0.0% | |
| Jan 17 | 2.5 | 0.00 | 1.11 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | RKLB covered calls | |
| 3. | EEM covered calls | 8. | KWEB covered calls | 3. | LUNR covered calls | |
| 4. | FXI covered calls | 9. | TLT covered calls | 4. | NMRA covered calls | |
| 5. | IWM covered calls | 10. | KRE covered calls | 5. | CRVS covered calls | |
Want more examples? OVF Covered Calls | OVL Covered Calls
